secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001447362-22-000083
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance
--------------------------------------------------------------------------------

- Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.
- Total test reports 8,627 (+68% YoY); DecisionDx-Melanoma +48%, DecisionDx-SCC +117%.
- 2022 total revenue guidance raised to $118-123M from $115-120M.
- Acquired AltheaDx/IDgenetix PGx test for mental health in April 2022; adds ~$5B TAM.
- Operating cash flow ($21.4M) vs ($3.6M); adjusted EBITDA ($11.4M) vs $0.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/0001447362-22-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/cstl-20220509.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer